Pathophysiological roles for IL-18 in inflammatory arthritis

Expert Opinion on Therapeutic Targets

Volumn 7, Issue 6, 2003, Pages 701-724

  Matsui, Kiyoshi ^a   Tsutsui, Hiroko ^a,b   Nakanishi, Kenji ^a,b  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Caspases; Chemokines; Chondrocytes; Collagen induced arthritis (CIA); IL 18; Inflammation; Innate immunity; Osteoarthritis (OA); Pro inflammatory cytokines; Rheumatoid arthritis (RA); Synoviocytes; TH1 TH2 responses; Toll like receptors (TLRs)

Indexed keywords

BINDING PROTEIN; COLLAGEN; CYTOKINE ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 18; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 18 MONOCLONAL ANTIBODY; INTERLEUKIN 18 RECEPTOR ANTIBODY; INTERLEUKIN RECEPTOR; MONOCLONAL ANTIBODY; PROTEIN IRAK M; RECEPTOR ANTIBODY; REGULATOR PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ARTHRITIS; CARTILAGE CELL; CYTOKINE RELEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TARGETING; HUMAN; INFLAMMATORY DISEASE; NONHUMAN; OSTEOARTHRITIS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CHONDROCYTES; CYSTEINE ENDOPEPTIDASES; CYTOKINES; HUMANS; IMMUNITY, CELLULAR; INFECTION; INFLAMMATION; INTERLEUKIN-18; INTERLEUKIN-18 RECEPTOR ALPHA SUBUNIT; MEMBRANE GLYCOPROTEINS; MICE; MICE, KNOCKOUT; MODELS, IMMUNOLOGICAL; NEOPLASMS; OSTEOARTHRITIS; RECEPTORS, CELL SURFACE; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-18; SIGNAL TRANSDUCTION; SYNOVIAL MEMBRANE; TH1 CELLS; TH2 CELLS; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0348217887     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.7.6.701     Document Type: Review

References (246)

1. IMLER JL, HOFFMANN JA: Toll receptors in Drosophila: a family of molecules regulating development and immunity. Curr. Top. Microbiol. Immunol. (2002) 270:63-79.
2. HOFFMANN JA, REICHHART JM: Drosophila innate immunity: an evolutionary perspective. Nat. Immunol. (2002) 3:121-126.
3. JANEWAY CA Jr, MEDZHITOV R: Innate immune recognition. Annu. Rev. Immunol. (2002) 20:197-216.
4. MEDZHITOV R, JANEWAY CA Jr: Innate immunity: the virtues of a nonclonal system of recognition. Cell (1997) 91:295-298.
5. O'NEILL LA, DINARELLO CA: The IL-1 receptor/toll-tike receptor superfamily: crucial receptors for inflammation and host defense. Immunol. Today (2000) 21:206-209.
6. AKIRA S, TAKEDA K, KAISHO T: Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. (2001) 2:675-680.
7. TAKEDA K, KAISHO T, AKIRA S: Toll-like receptors. Annu. Rev. Immunol. (2003) 21:335-376.
8. OKAMURA H, TSUTSUI H, KOMATSU T et al.: Cloning of a new cytokine that induces IFN-γ production by T cells. Nature (1995) 378:88-91.
9. KIM J, OCHOA MT, KRUTZIK SR et al.: Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J. Immunol. (2002) 169:1535-1541.
10. OKAMURA H, TSUTSUI H, KASHIWAMURA S, YOSHIMOTO T, NAKANISHI K: Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Adv. Immunol. (1998) 70:281-312.
11. OKAMURA H, KASHIWAMURA S, TSUTSUI H, YOSHIMOTO T, NAKANISHI K: Regulation of interferon-γ production by IL-12 and IL-18. Curr. Opin. Immunol. (1998) 10:259-264.
12. FANTUZZI G, DINARELLO CA: Interleukin-18 and interleukin-1β: two cytokine substrates for ICE (caspase-1). J. Clin. Immunol. (1999) 19:1-11.
13. DINARELLO CA: Interleukin-1β, interleukin-18, and the interleukin-1β converting enzyme. Ann. NY Acad. Sci. (1998) 856:1-11.
14. DINARELLO CA, FANTUZZI G: Interleukin-18 and host defense against infection. J. Infect. Dis. (2003) 187:S370-S384.
15. TSUTSUI H, MATSUI K, OKAMURA H, NAKANISHI K: Pathophysiological roles of interleukin-18 for inflammatory liver diseases. Immunol. Rev. (2000) 174:192-209.
16. TSUTSUI H, YOSHIMOTO T, OKAMURA H, AKIRA S, NAKANISHI K: IL-18 and IL-18 receptor knockout mouse. In: Cytokine Knockouts (2nd edn). Fanruzzi G (Ed.), Humana Press, Totowa, NJ (2003):303-322.
17. TSUTSUI H, ADACHI K, SEKI E, NAKANISHI K: Cytokine-induced inflammatory liver injuries. Curr. Mol. Med. (2003) 3:545-559.
18. H2 responses. Annu. Rev. Immunol. (2001) 19:423-474.
19. OKAMURA H, LOTZE MT, TSUTSUI H et al.: Interleukin-18 [IL-1F4]. In: The Cytokine Handbook (4th edn). Thomson AW, Lotze MT (Eds), Academic Press, NY (2003):709-733.
20. TSUTSUI H, YOSHIMOTO T, OKAMURA H, NAKANISHI K: Interleukin-18. In: Encyclopedia Hormones. Henry HL, Norman AW (Eds), Academic Press, New York (2003). In Press.
21. USHIO S, NAMBA M, OKURA T et al.: Cloning of the cDNA for human IFN-γ-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. J. Immunol. (1996) 156:4274-4279.
22. BAZAN JF, TIMANS JC, KASTELEIN RA: A newly defined interleukin-1? Nature (1996) 379:591.
23. TONE M, THOMPSON SA, TONE Y, FAIRCHILD PJ, WALDMANN H: Regulation of IL-18 (IFN-γ-inducing factor) gene expression. J. Immunol (1997) 159:6156-6163.
24. KIM YM, KANG HS, PAIK SG et al.: Roles of IFN consensus sequence binding protein and PU.1 in regulating IL-18 gene expression. J. Immunol. (1999) 163:2000-2007.
25. SHACKELFORD R, ADAMS DO, JOHNSON SP: IFN-γ and lipopolysaccharide induce DNA binding of transcription factor PU.1 in murine tissue macrophages. J. Immunol. (1995) 154:1374-1382.
26. SHARF R, AZRIEL A, LEJBKOWICZ F et al.: Functional domain analysis of interferon consensus sequence binding protein (ICSBP) and its association with interferon regulatory factors. J. Biol. Chem. (1995) 270:13063-13069.
27. STOLL S, MULLER G, KURIMOTO M et al.: Production of IL-18 (IFN-γ-inducing factor) messenger RNA and functional protein by murine keratinocytes. J. Immunol. (1997) 159:298-302.
28. SAHA N, MOLDOVAN F, TARDIF G et al.: Interleukin-1β-converting enzyme/caspase-1 in human osteoarthritic tissues: localization and role in the maturation of interleukin-1β and interleukin-18. Arthritis Rheum. (1999) 42:1577-1587.
29. UDAGAWA N, HORWOOD NJ, ELLIOTT J et al.: Interleukin-18 (interferon-γ-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-γ to inhibit osteoclast formation. J. Exp. Med. (1997) 185:1005-1012.
30. TSUTSUI H, MATSUI K, KAWADA N et al.: IL-18 accounts for both TNF-α- and Fas ligand-mediated hepatotoxic pathways in endotoxin-induced liver injury in mice. J. Immunol. (1997) 159:3961-3967.
31. SEKI E, TSUTSUI H, NAKANO H et al.: Lipopolysaccharide-induced IL-18 secretion from murine Kupffer cells independently of Myeloid differentiation factor 88 that is critically involved in induction of production of IL-12 and IL-1β. J. Immunol. (2001) 166:2651-2657.
32. MEE JB, ALAM Y, GROVES RW: Human keratinocytes constitutively produce but not process interleukin-18. Br. J. Dermatol. (2000) 143:330-336.
33. NAKANO H, TSUTSUI H, TERADA M et al.: Persistent secretion of IL-18 in the skin contributes to IgE response in mice. Int. Immunol. (2003) 15:611-621.
34. CAMERON LA, TAHA RA, TSICOPOULOS A et al.: Airway epithelium expresses interleukin-18. Eur. Respir. J. (1999) 14:553-559.
35. TAKEUCHI M, NISHIZAKI Y, SANO O et al.: Immunohistochemical and immuno-electron-microscopic detection of interferon-γ-inducing factor (interleukin-18) in mouse intestinal epithelial cells. Cell Tissue Res. (1997) 289:499-507.
36. OLEE T, HASHIMOTO S, QUACH J, LOTZE M: IL-18 is produced by articular chondrocytes and induces proinflammatory and catabolic responses. J. Immunol. (1999) 162:1096-1100.
37. GU Y, KUIDA K, TSUTSUI H et al.: Activation of interferon-γ inducing factor mediated by interleukin-1β converting enzyme. Science (1997) 275:206-209
38. GHAYUR T, BANERJEE S, HUGUNIN M et al.: Caspase-1 processes IFN-γ-inducing factor and regulates LPS-induced IFN-γ production. Nature (1997) 386:619-623.
39. TSUTSUI H, KAYAGAKI N, KUIDA K et al.: Caspase-1-independent, Fas/Fas ligand-mediated IL-18 secretion from macrophages causes acute liver injury in mice. Immunity (1999) 11:359-367.
40. ALNEMRI ES, LIVINGSTON DJ, NICHOLSON DW et al.: Human ICE/CED-3 protease nomenclature. Cell (1996) 87:171.
41. EARNSHAW WC, MARTINS LM, KAUFMANN SH: Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu. Rev. Biochem. (1999) 68:383-424.
42. LI P, NIJHAWAN K, BUDIHARDJO I et al.: Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell (1997) 91:479-489.
43. THORNBERY NA, BULL HG, CALAYCAY JR et al.: A novel heterodimeric cysteine protease is required for interleukin-1β processing in monocytes. Nature (1992) 356:768-774.
44. MIWA K, ASANO M, HORAI R et al.: Caspase-1-independent IL-1β release and inflammation induced by the apoptosis inducer Fas ligand. Nat. Med. (1998) 4:1287-1292.
45. SEKI E, TSUTSUI H, TSUJI NM et al.: Critical roles of myeloid differentiation factor 88-dependent proinflammatory cytokine release in early phase clearance of Listeria monocytogenes in mice. J. Immunol. (2002) 169:3863-3868.
46. ADACHI K, TSUTSUI H, KASHIWAMURA S et al.: Plasmodium berghei infection in mice induces liver injury by an IL-12- and Toll-like receptor/myeloid differentiation factor 88-dependent mechanism. J. Immunol. (2001) 167:5928-5934.
47. ITOI H, FUJIMORI Y, TSUTSUI H et al.: Fas ligand-induced caspase-1-dependent accumulation of interleukin (IL)-18 in mice with acute graft-versus-host disease. Blood (2001) 98:235-237.
48. THOMASSEN E, BIRD TA, RENSHAW BR, KENNEDY MK, SIMS JE: Binding of interleukin-18 to the interleukin-1 receptor homologous receptor IL-1RrP1 leads to activation of signaling pathways similar to those used by interleukin-1. J. Interferon Cytokine Res. (1998) 18:1077-1088.
49. TORIGOE K, USHIO S, OKURA T et al.: Purification and characterization of the human interleukin-18 receptor. J. Biol. Chem. (1997) 272:25737-24742.
50. BORN TL, THOMASSEN E, BIRD TA, SIMS JE: Cloning of a novel receptor subunit, AcPL, required for interleukin-18 signaling. J. Biol. Chem. (1998) 273:29445-29450.
51. DEBETS R, TIMANS JC, CHURAKOWA T et al.: IL-18 receptors, their role in ligand binding and function: anti-IL-1RAcPL antibody, a potent antagonist of IL-18. J. Immunol. (2000) 165:4950-4956.
52. HOSHINO K, TSUTSUI H, KAWAI T et al.: Generation of IL-18 receptor-deficient mice: evidence for IL-1 receptor-related protein as an essential IL-18 binding receptor. J. Immunol. (1999) 162:5041-5044.
53. NEIGHBORS M, XU X, BARRAT F et al.: A critical role for interleukin 18 in primary and memory effector responses to Listeria monocytogenes that extends beyond its effects on interferon γ production. J. Exp. Med. (2001) 194:343-354.
54. AHN HJ, MARUO S, TOMURA M et al.: A mechanism underlying synergy between IL-12 and IFN-γ-inducing factor in enhanced production of IFN-γ. J. Immunol. (1997) 159:2125-2131.
55. H1 development but synergizes with IL-12 for interferon-γ production and activates IRAK and NF-κB. Immunity (1997) 7:571-581.
56. H2 cells. J. Exp. Med. (1998) 188:1485-1492.
57. H1 cells, and B cells: synergism with IL-18 for IFN-γ production. J. Immunol. (1998) 161:3400-3407.
58. TOMINAGA K, YOSHIMOTO T, TORIGOE K et al.: IL-12 synergizes with IL-18 or IL-1β for IFN-γ production from human T cells. Int. Immunol. (2000) 12:151-160.
59. HYODO Y, MATSUI K, HAYASHI N et al.: IL-18 up-regulates perforin-mediated NK activity without increasing perforin messenger RNA expression by binding to constitutively expressed IL-18 receptor. J. Immunol. (1999) 162:1662-1668.
60. + T cells in the induction of immunoglobulin E antibodies in response to interleukin-18 treatment of mice. J. Exp. Med. (2003) 197:997-1005.
61. ADACHI O, KAWAI T, TAKEDA K et al.: Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity (1998) 9:143-150.
62. KANAKARAJ P, SCHAFER PH, CAVENDER DE et al.: Interleukin (IL)-1 receptor-associated kinase (IRAK) requirement for optimal induction of multiple IL-1 signaling pathways and IL-6 production. J. Exp. Med. (1998) 187:2073-2079.
63. H2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev. (2001) 12:53-72.
64. KAWAI T, ADACHI O, OGAWA T, TAKEDA K, AKIRA S: Unresponsiveness of MyD88-defident mice to endotoxin. Immunity (1999) 11:115-122.
65. SUZUKI N, SUZUKI S, DUNCAN GS et al.: Severe impairment of interleukin-1 and Toll like receptor signaling in mice lacking IRAK-4. Nature (2002) 416:750-754.
66. SUZUKI N, CHEN NJ, MILLER DG et al.: IRAK-4 is essential for interleukin-18-mediated natural killer and T helper cell Type 1 response. J. Immunol. (2003) 170:4031-4035.
67. MEDVEDEV AE, LENTSCHAT A, KUHNS DB et al.: Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infection. J. Exp. Med. (2003) 198:521-531.
68. H1 cytokine response. Immunity (1999) 10:127-136.
69. AIZAWA Y, AKITA K, TANIAI M et al.: Cloning and expression of interleukin-18 binding protein. FEBS Lett. (1999) 445:338-342.
70. REZNIKOV LL, KIM SH, WESTCOTT JY et al.: IL-18 binding protein increases spontaneous and IL-1-induced prostaglandin production via inhibition of IFN-γ. Proc. Natl. Acad. Sci. USA (2000) 97:2174-2179.
71. KIM SH, EISENSTEIN M, REZNIKOV L et al.: Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc. Natl. Acad. Sci. USA (2000) 97:1190-1195.
72. KIM SH, REZNIKOV LL, STUYT RJ et al.: Functional reconstitution and regulation of IL-18 activity by the IL-18Rβ chain. J. Immunol. (2001) 166:148-154.
73. BANDA NK, VODRACEK A, KRAUS D et al.: Mechanisms of inhibition of collagen-induced arthritis by murine IL-18 binding protein. J. Immunol. (2003) 170:2100-2105.
74. BUFLER P, AZAM T, GAMBONI-ROBERTSON F et al.: A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity. Proc. Natl. Acad. Sci. USA (2002) 99:13723-13728.
75. JOOSTEN LA, VAN DE LOO FA, LUBBERTS E et al.: An IFN-γ-independent proinflammatory role of IL-18 in murine streptococcal cell wall arthritis. J. Immunol. (2000) 165:6553-6558.
76. PLATER-ZYBERK C, JOOSTEN LA, HELSEN MM et al.: Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J. Clin. Invest. (2001) 108:1825-1832.
77. DINARELLO CA: Targeting interleukin 18 with interleukin 18 binding protein. Ann. Rheum. Dis. (2000) 59:i17-i20
78. H1 response in IL-18-deficient mice. Immunity (1998) 8:383-390.
79. + T cells. Eur. J. Immunol. (2000) 30:1998-2006.
80. + T cells, IL-4 and STAT6. Nat. Immunol. (2000) 1:132-137.
81. KONISHI K, TSUTSUI H, MURAKAMI T et al.: IL-18 contributes to the spontaneous development of atopic dermatitis-like inflammatory skin lesion independently of IgE/stat6 under specific pathogen-free conditions. Proc. Natl. Acad. Sci. USA (2002) 99:11340-11345.
82. NAKANISHI K: Innate and acquired activation pathways in T cells. Nat. Immunol. (2001) 2:140-142.
83. HUNTER CA, TIMANS J, PISACANE P et al.: Comparison of the effects of interleukin-1α, interleukin-1β and interferon-γ-inducing factor on the production of interferon-γ by natural killer. Eur. J. Immunol (1997) 27:2787-2792.
84. FEHNIGER TA, SHAH MH, TURNER MJ et al.: Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J. Immunol. (1999) 162:4511-4520.
85. STRENGELL M, MATIKAINEN S, SIRÉN J et al.: IL-21 in synergy with IL-15 or IL-18 enhances IFN-γ production in human NK and T cells. J. Immunol. (2003) 170:5464-5469.
86. FUKAO T, MATSUDA S, KOYASU S: Synergistic effects of IL-4 and IL-18 on IL-12-dependent IFN-γ production by dendritic cells.J. Immunol. (2000) 164:64-71.
87. MUNDER M, MALLO M, EICHMANN K, MODOLELL M: Murine macrophages secrete interferon γ upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation. J. Exp. Med. (1998) 187:2103-2108.
88. SHIMODA K, TSUTSUI H, AOKI K et al.: Partial impairment of interleukin-12 (IL-12) and IL-18 signaling in Tyk2-deficient mice. Blood (2002) 99:2094-2099.
89. PARR MB, PARR EL: The role of γ interferon in immune resistance to vaginal infection by herpes simplex virus Type 2 in mice. Virology (1999) 258:282-294.
90. HARANDI AM, SVENNERHOLM B, HOLMGREN J, ERIKSSON K: Interleukin-12 (IL-12) and IL-18 are important in innate defense against genital herpes simplex virusType 2 infection in mice but are not required for the development of acquired γ interferon-mediated protective immunity. J. Virol. (2001) 75:6705-6709.
91. MORI I, HOSSAIN J, TAKEDA K et al.: Impaired microglial activation in the brain of IL-18-gene-disrupted mice after neurovirulent influenza A virus infection. Virology (2001) 287:163-170.
92. H1 response and host defense against infection by Mycobacterium tuberculosis a comparative study with IL-12p40. J. Immunol. (2002) 169:323-329.
93. KAWAKAMI K, KOGUCHI Y, QURESHI MH et al.: IL-18 contributes to host resistance against infection with Cryptococcus neoformans in mice with defective IL-12 synthesis through induction of IFN-γ production by NK cells. J. Immunol. (2000) 165:941-947.
94. WEI XQ, LEUNG BP, NIEDBALA W et al.: Altered immune responses and susceptibility to Leishmania major and Staphylococcus aureus infection in IL-18-deficient mice. J. Immunol. (1999) 163:2821-2828.
95. H1 response and control cutaneous Leishmania major infection. J. Immunol. (2000) 164:5890-5893.
96. OHKUSU K, YOSHIMOTO T, TAKEDA K et al.: Potentiality of interleukin-18 as a useful reagent for treatment and prevention of Leishmania major infection. Infect. Immun. (2000) 68:2449-2456.
97. SINGH RP, KASHIWAMURA S, RAO P et al.: The role of IL-18 in blood-stage immunity against murine malaria Plasmodium yoelii 265 and Plasmodium berghei ANKA. J. Immunol. (2002) 168:4674-4681.
98. + effector T cells is differentially regulated by IL-18 and IL-12. J. Immunol. (1999) 162:3202-3211.
99. FUJIMORI Y, YOSHIMOTO T, MATSUI K et al.: Increased expression of interleukin 18 receptor on T lymphocytes in patients with acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Interferon Cytokine Res. (2002) 22:751-754.
100. OKAMOTO I, KOHNO K, TANIMOTO T et al.: IL-18 prevents the development of chronic graft-versus-host disease in mice. J. Immunol. (2000) 164:6067-6074.
101. TSUTSUI H, NAKANISHI K, MATSUI K et al.: Interferon-γ-inducing factor upregulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. J. Immunol. (1996) 157:3967-3973.
102. + T cell-mediated cytotoxicity. J. Immunol. (1999) 162:2639-2647.
103. OSAKI T, PERON JM, CAI Q et al.: IFN-γ-inducing factor/IL-18 administration mediates IFN-γ- and IL-12-independent antitumor effects. J. Immunol. (1998) 160:1742-1749.
104. HASHIMOTO W, OSAKI T, OKAMURA H et al.: Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively. J. Immunol. (1999) 163:583-589.
105. OSHIKAWA K, SHI F, RAKHMILEVICH AL et al.: Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-IL-18, and IL-1β converting enzyme cDNA. Proc. Natl. Acad. Sci. USA (1999) 96:13351-13356.
106. O'DONNELL MA, LUO Y, CHEN X et al.: Role of IL-12 in the induction and potentiation of IFN-γ in response to bacillus Calmette-Guerin. J. Immunol. (1999) 163:4246-4252.
107. TASAKI K, YOSHIDA Y, MAEDA T et al.: Protective immunity is induced in murine colon carcinoma cells by the expression of interleukin-12 or interleukin-18, which activate Type 1 helper T cells. Cancer Gene Ther. (2000) 7:247-254.
108. COUGHLIN CM, SALHANY KE, WYSOCKA M et al.: Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J. Clin. Invest. (1998) 101:1441-1452.
109. HOSHINO T, WILTROUT RH, YOUNG HA: IL-18 is a potent coinducer of IL-13 in NK and T cells: a new potential role for IL-18 in modulating the immune response.J. Immunol (1999) 162:5070-5077.
110. ARMITAGE RJ, FANSLOW WC, STROCKBINE L et al.: Molecular and biological characterization of a murine ligand for CD40. Nature (1992) 357:80-82.
111. HOSHINO T, KAWASE Y, OKAMOTO M et al.: IL-18-transgenic mice: in vivo evidence of a broad role for IL-18 in modulating immune function. J. Immunol. (2001) 166:7014-7018.
112. KRONENBERG M, GAPIN L: The unconventional lifestyle of NKT cells. Nat. Rev. Immunol. (2002) 2:557-568.
113. BENDELAC A, RIVERA MN, PARK SH, ROARK JH: Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu. Rev. Immunol. (1997) 15:535-562.
114. YOSHIMOTO T, PAUL WE: CD4pos,NK1, 1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J. Exp. Med. (1994) 179:1285.
115. LAUW FN, BRANGER J, FLORQUIN S et al.: IL-18 improves the early antimicrobial host response to pneumococcal pneumonia. J. Immunol. (2002) 168:372-378.
116. OGURA T, UEDA H, HOSOHARA K et al.: Interleukin-18 stimulates hematopoietic cytokine and growth factor formation and augments circulating granulocytes in mice. Blood (2001) 98:2101-2107.
117. CONTI B, JAHNG JW, TINTI C, SON JH, JOH TH: Induction of interferon-γ inducing factor in the adrenal cortex. Biol. Chem. (1997) 272:2035-2037.
118. KUBOTA T, FANG J, BROWN RA, KRUEGER JM: Interleukin-18 promotes sleep in rabbits and rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2001) 281:R828-R838.
119. ROTHE H, JENKINS NA, COPELAND NG, KOLB H: Active stage of autoimmune diabetes is associated with die expression of a novel cytokine, IGIF, which is located near Idd2. J. Clin. Invest. (1997) 99:469-474.
120. WILDBAUM G, YOUSSEF S, GRABIE N, KARIN N: Neutralizing antibodies to IFN-γ-inducing factor prevent experimental autoimmume encephalomyelitis. J. Immunol. (1998) 161:6368-6374.
121. KANAI T, WATANABE M, AKAZAWA A et al.: Macrophage-derived IL,18-mediated intestinal inflammation in the routine model of Crohn's disease. Gastroenterology (2001) 121:875-888.
122. KANAI T, WATABANE M, OKAZAWA A, SATO T, HIBI T: Interleukin-18 and Crohn's disease. Digestion (2001) 63:37-42.
123. SIVAKUMAR PV, WESTICH GM, KANALY S et al.: Interleukin 18 is a primary mediator of the inflammation associated with dextran sulfate sodium induced colitis: blocking interleukin 18 attenuates intestinal damage. Gut (2002) 50:812-820.
124. BALISTRERI WF, GRAND R, HOOFNAGLE JH et al.: Biliary atresia: current concepts and research directions. Hepatology (1996) 23:1682-1692.
125. URUSHIHARA N, IWAGAKI H, YAGI T et al.: Elevation of serum interleukin-18 levels and activation of Kupffer cells in biliary atresia. J. Pediatr. Surg. (2000) 35:446-449.
126. MCGUINNESS PH, PAINTER D, DAVIES S, MCCAUGHAN GW: Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection. Gut (2000) 46:260-269.
127. LUDWICZEK O, KASER A, NOVICK D et al.: Plasma levels of interleukin-18 and interleukin-18 binding protein are elevated in patients with chronic liver disease. J. Clin. Immunol. (2002) 22:331-337.
128. YUMOTO E, HIGASHI T, NOUSO K et al.: IL-18 and IL-10 in acute hepatitis: serum γ-interferon-inducing factor (IL-18) and IL-18 levels in patients with acute hepatitis and fulminant hepatic failure. J. Gastroenterol. Hepatol. (2002) 17:285-294.
129. VAN DE WATER J, ANSARI AA, SURH CD et al.: Evidence for the targeting by 2-oxo-dehydrogenase enzymes in the T cell response of primary biliary cirrhosis. J. Immunol. (1991) 146:89-94.
130. VAN DE WATER J, ANSARI A. PRINDIVILLE T et al.: Heterogeneity of autoreactive T cell clones specific for the E2 component of the pyruvate dehydrogenase complex in primary biliary cirrhosis. J. Exp. Med. (1995) 181:723-733.
131. YAMANO T, HIGASHI T, NOUSO K et al.: Serum interferon-γ inducing factor/IL-18 levels in primary biliary cirrhosis. Clin. Exp. Immunol. (2000) 122:227-231.
132. YAGI T, IWAGAKI N, URUSHIHARA K et al.: Participation of IL-18 in human cholestatic cirrhosis and acute rejection: analysis in living donor liver transplantation. Transplant. Proc. (2001) 33:421-425.
133. NETEA MG, FANTUZZI G, KULLBERG BJ et al.: Neutralization of IL-18 reduces neutrophil tissue accumulation and protects mice against Escherichia coli and Salmonella typhimurium endotoxemia. J. Immunol. (2000) 164:2644-2649.
134. NAKAMURA H, KOMATSU K, AYAKI M et al.: Serum levels of soluble IL-2 receptor, IL-12, IL-18, and IFN-γ in patients with acute graft-versus-host disease after allogencic bone marrow transplantation. J. Allergy Clin. Immunol. (2000) 106:45-50.
135. FUJIMORI Y, TAKATSUKA H, TAKEMOTO Y et al.: Elevated interleukin (IL)-18 levels during acute graft-versus-host disease after allogeneic bone marrow transplantation. Br. J. Haematol. (2000) 109:652-657.
136. SAKAO Y, TAKEDA K, TSUTSUI H et al.: IL-18-deficient mice are resistant to endotoxin-induced liver injury but highly susceptible to endotoxin shock. Int. Immunol. (1999) 11:471-480.
137. YOSHIMOTO T, TSUTSUI H, TOMINAGA K et al.: IL-18, although anti-allergic when administered with IL-12, stimulates IL-4 and histamine release by basophils. Proc. Natl. Acad. Sci. USA (1999) 96:13962-13966.
138. TANAKA T, TSUTSUI H, YOSHIMOTO T et al.: Interleukin-18 is elevated in the sera from patients with atopic dermatitis and from atopic dermatitis model mice, NC/Nga. Int. Arch. Allergy Immunol. (2001) 125:236-240.
139. YOSHIZAWA Y, NOMAGUCHI H, IZAKI S, KITAMURA K: Serum cytokine levels in atopic dermatitis. Clin. Exp. Dermatol. (2002) 27:225-229.
140. KERR LD: Inflammatory arthritis in the elderly. Mt. Sinai J. Med. (2003) 70:23-26.
141. FIRESTEIN GS: Evolving concepts of rheumatoid arthritis. Nature (2003) 423:356-361.
142. DAVIS LS: The synovial fibroblast in rheumatoid arthritis. Am. J. Pathol. (2003) 162:1399-1402.
143. WOOLLEY DE: The mast cell in inflammatory arthritis. N. Engl. J. Med. (2003) 348:1709-1711.
144. TAYLOR PC: Anti-cytokines and cytokines in the treatment of rheumatoid arthritis. Curr. Pharm. Des. (2003) 9:1095-1106.
145. STEINER G, SMOLEN J: Autoantibodies in rheumatoid arthritis and their clinical significance. Arthritis Res. (2002) 4:S1-S5.
146. SILVERMAN GJ, WEISMAN S: Rituximab therapy and autoimumme disorders. Arthritis Rheum. (2003) 48:1484-1492.
147. COURTENAY JS, DALLMAN MJ, DAYAN AD, MARTIN A, MOSEDALE B: Immunization against heterotogous Type II collagen induces arthritis in mice. Nature (1980) 283:666-668.
148. IWAKURA Y: Roles of IL-1 in the development of rheumatoid arthritis: consideration from mouse models. Cytokine Growth Factor Rev. (2002) 13:341-355.
149. GENTILETTI J, FAVA RA: Does vascular endothelial growth factor play a role in interleukin-6 receptor antagonist therapy for rheumatoid arthritis? Arthritis Rheum. (2003) 48:1471-1474.
150. ATSUMI T, ISHIHARA K, KAMIMURA D et al.: A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J. Exp. Med. (2002) 196:979-990.
151. WONG PK, CAMPBELL IK, EGAN PJ, ERNST M, WICKS IP: The role of the interleukin-6 family of cytokines in inflammatory arthritis and bone turnover. Arthritis Rheum. (2003) 48:1177-1189.
152. SHOUDA T, YOSHIDA T, HANADA T et al.: Induction of the cytokine signal regulator SOCS1/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J. Clin. Invest. (2001) 108:1781-1788.
153. HIRSCHFELD M, KIRSCHNING CJ, SCHWANDNER R et al.: Inflammatory signaling by Borrelia burgdorferi lipoproteins is mediated by Toll-like receptor. J. Immunol. (1999) 163:2382-2386.
154. CHOE JY, SARAH BC, WU SR, CORR M: Interleukin 1 receptor dependence of serum transferred arthritis can be circumvented by Toll-like receptor 4 signaling. J. Immunol. (2003) 197:537-542.
155. SEIBL R, BIRCHLER T, LOELIGER S et al.: Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium. Am. J. Pathol. (2003) 162:1221-1227.
156. KLINMAN D: Does activation of the innate immune system contribute to the development of rheumatoid arthritis? Arthritis Rheum. (2003) 48:590-593.
157. LUBBERTS E, JOOSTEN LA, OPPERS B et al.: IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J. Immunol. (2001) 167:1004-1013.
158. HAPPEL KI, ZHENG M, YOUNG E et al.: Roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection. J. Immunol. (2003) 170:4432-4436.
159. NAKAE S, SAIJO S, HORAI R et al.: IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc. Natl. Acad. Sci. USA (2003) 100:5986-5990.
160. FOSSIEZ F, DJOSSAU O, CHOMARAT P et al.: T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J. Exp. Med. (1996) 183:2593-2603.
161. SCHWARZENBERGER P, LA RUSSA V, MILLER A et al.: IL-17 stimulates granulopoiesis in mice: use of an alternate, novel gene therapy-derived method for in vivo evaluation of cytokines. J. Immunol. (1998) 161:6383-6389.
162. SHALOM-BARAK T, QUANCH J, LOTZE M: Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinase and NF-κB. J. Biol. Chem. (1998) 273:27467-27473.
163. H cells. J. Immunol. (2000) 165:6107-6115.
164. LINDÉN A: Role of interleukin-17 and the neutrophil in asthma. Int. Arch. Allergy Immunol. (2001) 126:179-184.
165. MIOSSEC P: Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy. Arthritis Rheum. (2003) 48:594-601.
166. JONES HD, KONG YY, PENNINGER JM: Role of RANKL and RANK in bone loss and arthritis. Ann. Rheum. Dis. (2002) 61:ii32-ii39.
167. SMOLEN JS, GÜNTER S: Therapeutic strategies for rheumatoid arthritis. Nat. Rev. Drug Discov. (2003) 2:473-488.
168. TAYLOR PC: Antibody therapy for rheumatoid arthritis. Curr. Opin. Pharmacol (2003) 3:323-328.
169. FELDMANN M: Development of anti-TNF therapy for rheumatoid arthritis. Nat. Rev. Immunol. (2003) 2:364-371.
170. MOR L, ISELIN S, DE LIBERO G et al.: Attenuation of collagen-induced arthritis in 55-kDa TNF receptor Type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice. J. Immunol. 157:3178-3182.
171. LEE DM, FRIEND DS, GURISH MF et al.: Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science (2002) 297:1689-1692.
172. KEANE J, GERSHON S, WISE RP et al.: Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N. Engl. J. Med. (2001) 345:1098-1104.
173. NETEA MG, RADSTAKE T, JOOSTEN LA et al.: Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-γ production and Toll-like receptor 4 expression. Arthritis Rheum. (2002) 48:1853-1857.
174. ALONZI T, FATTORI E, LAZZARO D et al.: Interleukin 6 plays a key role in the development of collagen-induced arthritis. J. Exp. Med. (1998) 187:461-468.
175. ALEXOPOULOU J, THOMAS V, SCHNARE M et al.: Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice. Nat. Med. (2002) 8:878-884.
176. PARK CC, MOREL JC, AMIN AM et al.: Evidence of IL-18 as a novel angiogenic mediator. J. Immunol. (2001) 167:1644-1653.
177. GRACIE JA, FORSEY RJ, CHAN WL et al.: A proinflammatory role for IL-18 in rheumatoid arthritis. J. Clin. Invest. (1999) 104:1393-1401.
178. TANAKA M, HARIGAI M, KAWAGUCHI Y et al.: Mature form of interleukin 18 is expressed in rheumatoid arthritis synovial tissue and contributes to interferon-γ production by synovial T cells. J. Rheumatol. (2001) 28:1779-1787.
179. YAMAMURA M, KAWASHIMA M, TANIAI M et al.: Interferon-γ-inducing activity of interleukin-18 in the joint with rheumatoid arthritis. Arthritis Rheum. (2001) 44:275-285.
180. JOOSTEN LA, RADSTAKE TR, LUBBERTS E et al.: Association of interleukin-18 expression with enhanced levels of both interleukin-1β and tumor necrosis factor α in knee synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum. (2003) 48:339-347.
181. BRESNIHAN B, ROUX-LOMBARD P, MURPHY E et al.: Serum interleukin 18 and interleukin 18 binding protein in rheumatoid arthritis. Ann. Rheum. Dis. (2002) 61:726-729.
182. MÖLLER B, PAULUKAT J, NOLD M et al.: Interferon-γ induces expression of interleukin-18 binding protein in fibroblast-like synoviocytes. Rheumatology (2003) 42:442-445.
183. BYWATERS EGL: Still's disease in the adult. Ann. Rheum. Dis. (1971) 30:121-133.
184. HOSHINO T, OHTA A, YANG D et al.: Elevated serum interleukin 6, interferon-γ, and tumor necrosis factor-α levels in patients with adult Still's disease. J. Rheumatol. (1998) 25:396-398.
185. KAWASHIMA M, YAMAMURA M, TANIAI M et al.: Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. Arthritis Rheum. (2001) 44:550-560.
186. KAWAGUCHI Y, TERAJIMA H, HARIGAI M, HARA M, KAMATANI N: Interleukin-18 as a novel diagnostic marker and indicator of disease severity in adult-onset Still's disease. Arthritis Rheum. (2001) 44:1716-1718.
187. FUJII T, NIJIMA T, YASUOKA H et al.: Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease. Association with chronic articular disease. Rheumatology (2001) 40:1398-1404.
188. SUGIURA T, KAWAGUCHI Y, HARIGAI M et al.: Association between adult-onset Still's disease and interleukin-18 gene polymorphisms. Genes Immun. (2002) 3:394-399.
189. SCOLA MP, SHOMPSON SD, BRUNNER HI et al.: Interferon-γ:interleukin-4 rations and associated Type 1 cytokine expression in juvenile rheumatoid arthritis synovial tissue. J. Rheumatol. (2002) 29:369-378.
190. MAENO N, TAKEI S, NOMURA Y et al.: Highly elevated serum levels of interleukin-18 in systemic juvenile idiopathic arthritis but not in other juvenile idiopathic arthritis subtypes or in Kawasaki disease: comment on the article by Kawashima et al. Arthritis Rheum. (2002) 46:2539-2541.
191. LE J, VILCEK J: Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. Lab. Invest. (1987) 56:234-248.
192. REBOUL P, PELLETIER JP, TARDIF G, CLOUTIER JM, MARTEL-PELLETIER J: The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes: a role in osteoarthritis. J. Clin. Invert. (1996) 97:2011.
193. AMIN AR, DAVE M, ATTUR M, ABRAMSON SB: COX-2, NO, and cartilage damage and repair. Curr. Rheumatol. Rep. (2000) 2:447-453.
194. ABRAMSON SB, ATTUR M, AMIN AR, CLANCY R: Nitric oxide and inflammatory mediators in the perpetuation of osteoarthritis. Curr. Rheumatol. Rep. (2001) 3:534-541.
195. TIVE L: Celecoxib clinical profile. Rheumatology (2000) 39(Suppl. 2):21-28.
196. LANAS A: Clinical experience with cyclooxygenase-2 inhibitors. Rheumatology (2002) 41 (Suppl. 1): 16-22.
197. 2 in synovial fluid of osteoarthritis: a potential therapeutic target of cartilage degradation. J. Immunother. (2002) 25:S61-S64.
198. BOILEAU C, MARTEL-PELLETIER J, MOLDOVAN F et al.: The in situ up-regulation of chondrocyte interleukin-1-converting enzyme and interleukin-18 levels in experimental osteoarthiritis is mediated nitric oxide. Arthritis Rheum. (2002) 46:2637-2647.
199. COUSSENS LM, WERB Z: Inflammation and cancer. Nature (2002) 420:860-867.
200. BUCKLEY CD: Why do leucocytes accumulate within chronically inflamed joints? Rheumatology (2003) 42:1-12.
201. KOCH AE, KUNKEL SL, HARLOW LA et al.: Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J. Clin. Invest. (1992) 90:772-779
202. SNOWDEN N, HAJEER A, THOMSON W, OLLIER B: RANTES role in rheumatoid arthritis. Lancet (1994) 343:547-548.
203. ALAAEDDINE N, OLEE T, HASHIMOTO S, CREIGHTON-ACHERMANN L, LOTZE M: Production of the chemokine RANTES by articular chondrocytes and role in cartilage degradation. Arthritis Rheum. (2001) 44:1633-1643.
204. KOBAYASHI Y, ICHIJO Y, NAGATAKE H et al.: Processing of interleukin-1β in synovial cells freshly isolated from patients with rheumatoid arthritis. Biochem. Biophys. Res. Commun. (1994) 199:1035-1040.
205. KAWASHIMA M, MIOSSEC P: Heterogeneity of response of rheumatoid synovium cell subsets to interleukin-18 in relation to differential interleukin-18 receptor expression. Arthritis Rheum (2003) 48:631-637.
206. MÖLLER B, KUKOC-ZIVOJNOV N, KESSLER U et al.: Expression of interleukin-18 and its monokine-directed function in rheumatoid arthritis. Rheumatology (2001) 40:302-309.
207. LEUNG BP, CULSHAW S, GRACIE JA et al.: A role for IL-18 in neutrophil activation. J. Immunol (2001) 167:2879-2886.
208. LEUNG BP, MCINNES IB, ESFANDIARI E, WEI XQ, LIEW FY: Combined effects of IL-12 and IL-18 on the induction of collagen-induced arthritis. J. Immunol. (2000) 164:6495-6502.
209. MOREL JC, PARK CC, KUMAR P, KOCH AE: Interleukin-18 induces rheumatoid arthritis synovial fibroblast CXC chemokine production through NF-κB activation. Lab. Invest. (2001) 81:1371-1383.
210. RUTH JH, SHAHRARA S, PARK CC et al.: Role of macrophage inflammatory protein-3α and its ligand CCR6 in rheumatoid arthritis. Lab. Invest. (2003) 83:579-588.
211. MOREL JC, PARK CC, WOODS JM, KOCH AE: A novel role for interleukin-18 in adhesion molecule induction through NF-κB and phosphatidylinositol (PI) 3-kinase-dependent signal transduction pathways. J. Biol. Chem. (2001) 276:37069-37075.
212. MOREL JC, PARK CC, ZHU K et al.: Signal transduction pathways involved in rheumatoid arthritis synovial fibroblast IL-18-induced vascular cell adhesion molecule-1 expression. J. Biol. Chem. (2002) 277:34679-34691.
213. PFEILSCHIFTER J, KÖDITZ R, PFOHL M, SCHATZ H: Changes in proinflammatory cytokine activity after menopause. Endocr. Rev. (2002) 23:90-119.
214. LAM J, TAKESHITA S, BARKER JE et al.: TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. (2000) 106:1481-1488.
215. CENCI S, TORALDO G, WEITZMANN MN et al.: Estrogen deficiency induces bone loss by increasing T cell proliferation and life span through IFN-α-induced Class II transactivater Proc. Natl. Acad. Sci. USA (2003) 100:10405-10410.
216. ROGGIA C, GAO Y, CENCI S et al.: Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc. Natl. Acad. Sci USA (2001) 98:13960-13965.
217. HORWOOD NJ, ELLIOTT J, MARTIN TJ et al.: IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro. J. Immunol. (2001) 166:4915-4921.
218. YAMADA N, NIWA S, TSUJIMURA T et al.: Interleukin-18 and interleukin-12 synergistically inhibit osteoclastic bone-resorbing activity. Bone (2002) 30:901-908.
219. MAKIISHI-SHIMOBAYASHI C, SHUJIMURA T, IWASAKI T et al.: Interleukin-18 up-regulates osteoprotegerin expression in stromal/osteoblastic cells. Biochem. Biophys. Res.Commun. (2001) 281:361-366.
220. KAWASE T, HOSHINO T, YOKOTA K et al.: Bone malformations in interleukin-18 transgenic mice. J. Bone Miner. Res. (2003) 18:975-983.
221. TAKAYANAGI H, OGASAWARA K, HIDA S et al.: T-cell-mediated regulation of osteoclastogenesis by signaling cross-talk between RANKL and IFN-γ. Nature (2000) 406:600-605.
222. WEI X, LEUNG BP, ARTHUR HM, MCINNES IB, LIEW FY: Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18. J. Immunol. (2001) 166:517-521.
223. SMEETS RL, VAN DE LOO FAJ, ARNTZ OJ et al.: Adenoviral delivery of IL-18 binding protein C ameliorates collagen-induced arthritis in mice. Gene Ther. (2003) 10:1004-1011.
224. KOBAYASHI K, HERNANDEZ LD, GALÁN JE et al.: IRAK-M is a negative regulator of Toll-like receptor signaling. Cell (2002) 110:191-202.
225. NAKAGAWA R, MAKA T, TSUTSUI H et al.: SOCS-1 participates in negative regulation of LPS response. Immunity (2002) 17:677-687.
226. KINJYO I, HANADA T, INAGAKI-OHARA K et al.: SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity (2002) 17:583-591.
227. WALD D, QIN J, ZHAO Z et al.: SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat. Immunol. (2003) 4:920-927.
228. MCINNES IB, LEUNG BP, STURROCK RD, FIELD M, LIEW FY: Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-α production in rheumatoid arthritis. Nat. Med. (1997) 2:189-195.
229. KIM WU, MIN SY, CHO ML et al.: The role of IL-12 in inflammatory activity of patients with rheumatoid arthritis. Clin. Exp. Immunol. (2000) 119:175-181.
230. CORDERO OJ, SALGADO FJ, MERA-VARELA A, NOGUEIRA M: Serum interleukin-12, interleukin-15, soluble CD26, and adenosine deaminase in patients with rheumatoid arthritis. Rheumatol. Int. (2001) 21:69-74.
231. MCINNES IB, AL-MUCHALES J, FIELD M et al.: The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat. Med. (1996) 2:175-182.
232. SHAH MH, HACKSHAW KV, CALIGIURI MA: A role for IL-15 in rheumatoid arthritis? Nat. Med. (1998) 4:643.
233. L and Bcl-2. J. Immunol. (2002) 169:1760-1767.
234. MCINNES IB, LIEW FY: Interleukin 15: a proinflammatory role in rheumatoid arthritis synovitis. Immunol. Today (1998) 19:75-79.
235. DAYER JM: Interleukin-18, rheumatoid arthritis, and tissue destruction. J. Clin. Invest. (1999) 104:1337-1339.
236. MCINNES IB, GRACIE JA, LIEW FY: Interleukin-18: a novel cytokine in inflammatory rheumatic disease. Arthritis Rheum. (2001) 44:1481-1483.
237. LIEW FY, MCINNES IB: Role of interleukin 15 and interleukin 18 in inflammatory response. Ann. Rheum. Dis. (2002) 61:ii100-ii102.
238. LILE CW, KIENER PA, LEDBETTER JA, ARUFFO A, KLEBANOFF SJ: Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J. Exp. Med. (1996) 184:429-440.
239. OHASHI K, BURKART V, FLOHÉ S, KOLB H: Heat shock protein 60 is a putative endogenous ligand of the Toll-like receptor-4 complex. J. Immunol. (2000) 164:558-561.
240. DYBDAHL B, ZAHBA A, LIEN E et al.: Inflammatory response after open heart surgery: release of heat-shock protein 70 and signaling through Toll-like receptor-4. Circulation (2002) 105:685-690.
241. VABULAS RM, AHMAD-NEJAD P, GHOSE S et al.: HSP70 as endogenous stimulus of the Toll-Interleukin-1 receptor signal pathway. J. Biol. Chem. (2002) 277:15107-15112.
242. VABULAS RM, WAGNER H, SCHILD H: Heat shock proteins as ligands of Toll-like receptors. Curr. Top. Microbiol Immunol. (2002) 270:169-184.
243. SCHETT G, TOHIDAST-AKRAD M, STEINER G, SMOLEN J: The stressed synovium. Arthritis Res. (2001) 3:80-86.
244. SHARIF M, WORRALL JG, SINGH G et al.: The development of monoclonal antibodies to the human mitochondrial 60-κD heat-shock protein, and their use in studying the expression of the protein in rheumatoid arthritis. Arthritis Rheum. (1992) 35:1427-1433.
245. SCHETT G, REDLICH K, XU Q et al.: Enhanced expression of heat shock protein 70 (hsp70) and heat shock factor 1 (HSF1) activation in rheumatoid arthritis synovial tissue. J. Clin. Invest. (1998) 102:302-311.
246. PITTONI V, BOMBARDIERI M, SPINELLI FR et al.: Anti-tumor necrosis factor (TNF) α treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL)-18 but not IL-12 and IL-13. Ann. Rheum. Dis. (2002) 61:723-725.